The Multiple Myeloma Channel is supported with funding from BMS (Gold) and Legend Biotech (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
IMW 2019 | Daratumumab enhancement for MM: the clinical impact
Priya Choudhry
• 14 Sep 2019
Priya Choudhry, PhD, from the University of California, San Francisco, CA, explains how the use of DNA methyltransferase inhibitors to increase the efficacy of daratumumab is likely to impact patients in the clinical setting at the International Myeloma Workshop (IMW) 2019, held in Boston, MA.
